Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Kungalv – page 39

476 clinical trials in Kungalv, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Kungalv at a glance
476
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

476 trials in Kungalv

Open in trial search

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Study on Reduced BCG Dwell-Time for Patients with High-Risk Urothelial Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bcg (Bacillus Calmette-Guérin) Bacteria
  • Sponsor:Aarhus University Hospital

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Bevacizumab and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Vastra Gotalandsregionen

Study on Dexamethasone Eye Drops for Infants with Retinopathy of Prematurity

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Dexamethasone Phosphate
  • Sponsor:Vastra Gotalandsregionen

Study on the Effects and Safety of Upadacitinib for Children with Polyarticular Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Atezolizumab with Chemoradiotherapy for Patients with Limited Disease Small-Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Norwegian University Of Science And Technolology

Erectile dysfunction

Not recruiting

Study on the Safety and Effectiveness of LIB-01 for Treating Erectile Dysfunction in Adult Men

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:LIB-01 monohydrate
  • Sponsor:Dicot Pharma AB

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Pfizer Inc.

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.